A double-pronged attack on advanced prostate cancer could help treat as many as two in five patients with late-stage disease, ...

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in ...

The Nubeqa (darolutamide) regimen can be used to treat adult patients with advanced HSPC if docetaxel, a chemotherapy agent, ...

NICE recommends Bayer’s Nubeqa® (darolutamide) plus androgen deprivation therapy as a treatment option for patients with hormone-sensitive metastatic prostate cancer Nubeqa® (darolutamide) plus ...

Drugs already in use could be combined to form a two-pronged attack on advanced prostate cancer, a study suggests.

A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer, ...

A powerful new drug combination—niraparib added to standard prostate cancer therapy—has been shown to significantly delay ...

The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by ...

A targeted drug combination delays advanced prostate cancer in men with specific DNA repair gene mutations. A large international study led by researchers at UCL has found that a new combination of dr ...

The “striking” findings showed an overall upward trend in life expectancy when patients took niraparib - a targeted therapy ...

From AI-generated biopsy reports to new imaging techniques, these are the latest developments in advanced prostate cancer research that your doctor may be keeping tabs on. Much of managing advanced ...

The United States Prostate Cancer Biomarkers Market is projected to grow from $1.48 billion in 2024 to $3.54 billion by 2033, ...